DE3486255D1 - Pharmazeutische Zusammensetzungen. - Google Patents

Pharmazeutische Zusammensetzungen.

Info

Publication number
DE3486255D1
DE3486255D1 DE89202213T DE3486255T DE3486255D1 DE 3486255 D1 DE3486255 D1 DE 3486255D1 DE 89202213 T DE89202213 T DE 89202213T DE 3486255 T DE3486255 T DE 3486255T DE 3486255 D1 DE3486255 D1 DE 3486255D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE89202213T
Other languages
English (en)
Other versions
DE3486255T2 (de
Inventor
Robert Charles Hider
George Kontoghiorghes
Jack Silver
Michael Arthur Stockham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
British Technology Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Technology Group Ltd filed Critical British Technology Group Ltd
Application granted granted Critical
Publication of DE3486255D1 publication Critical patent/DE3486255D1/de
Publication of DE3486255T2 publication Critical patent/DE3486255T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • C07F15/025—Iron compounds without a metal-carbon linkage

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE89202213T 1983-09-23 1984-09-20 Pharmazeutische Zusammensetzungen. Expired - Fee Related DE3486255T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB838325494A GB8325494D0 (en) 1983-09-23 1983-09-23 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE3486255D1 true DE3486255D1 (de) 1994-01-20
DE3486255T2 DE3486255T2 (de) 1994-03-24

Family

ID=10549200

Family Applications (2)

Application Number Title Priority Date Filing Date
DE89202213T Expired - Fee Related DE3486255T2 (de) 1983-09-23 1984-09-20 Pharmazeutische Zusammensetzungen.
DE8484306438T Expired - Lifetime DE3483713D1 (de) 1983-09-23 1984-09-20 Hydroxypyridon-derivate und sie enthaltende pharmazeutische zubereitungen.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE8484306438T Expired - Lifetime DE3483713D1 (de) 1983-09-23 1984-09-20 Hydroxypyridon-derivate und sie enthaltende pharmazeutische zubereitungen.

Country Status (10)

Country Link
US (1) US4666927A (de)
EP (2) EP0138421B1 (de)
JP (2) JPH062739B2 (de)
CY (1) CY1516A (de)
DE (2) DE3486255T2 (de)
DK (1) DK158349C (de)
GB (2) GB8325494D0 (de)
GR (1) GR80445B (de)
SG (1) SG80989G (de)
ZA (1) ZA847408B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308054D0 (en) * 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
GB8308055D0 (en) * 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
US4780238A (en) * 1983-08-25 1988-10-25 The United States Of America As Represented By The United States Department Of Energy Natural chelating agents for radionuclide decorporation
US5010191A (en) * 1985-08-19 1991-04-23 The Regents Of The University Of California Imaging agents for in vivo magnetic resonance and scintigraphic imaging
US4908371A (en) * 1987-11-10 1990-03-13 Ciba-Geigy Corporation Esterified hydroxy dihydropyridinones for treating diseases associated with trivalent metal ion overload
GB8910521D0 (en) * 1989-05-08 1989-06-21 Nat Res Dev The stabilization of organic compounds
US5393777A (en) * 1990-11-15 1995-02-28 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Deferration using anguibactin siderophore
EP0498380A1 (de) * 1991-02-08 1992-08-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Komplexbildner
WO1994001406A1 (de) * 1992-07-01 1994-01-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Kontrastmittel für die mr diagnostik
US5298525A (en) * 1992-11-23 1994-03-29 University Technologies International, Inc. Diabetes prevention and treatment
US5849587A (en) * 1995-06-09 1998-12-15 Cornell Research Foundation, Inc. Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells
EP0833627B1 (de) 1995-06-10 2004-08-18 Vitra Pharmaceuticals Ltd. Eisenverbindungen, zusammensetzungen, herstellungsverfahren und verwendungen davon
ATE266006T1 (de) * 1995-06-14 2004-05-15 Univ California 3-hydroxy-2(1h)-pyridone als chelatbildner
US6140305A (en) * 1996-04-04 2000-10-31 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene products
US7026116B1 (en) * 1996-04-04 2006-04-11 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US6849399B1 (en) 1996-05-23 2005-02-01 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron misregulation diseases
ZA976421B (en) * 1996-07-22 1998-01-22 Boehringer Mannheim Italia New bis-platinum complexes with polyamine ligands as antitumor agents.
GB9625638D0 (en) * 1996-12-10 1997-01-29 Cenes Ltd Therapeutic antioxidants for alzheimer's diease
ATE335759T1 (de) 1997-06-13 2006-09-15 Bio Rad Laboratories Verfahren und zusammensetzungen für die diagnose und die behandlung von krankheiten, die mit eisenüberschuss oder eisenmangel assoziiert sind.
GB2345058A (en) * 1998-12-01 2000-06-28 Cerebrus Pharm Ltd Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system
US6767741B1 (en) * 1999-08-27 2004-07-27 Invitrogen Corporation Metal binding compounds and their use in cell culture medium compositions
DE60107272T2 (de) * 2000-09-19 2005-10-27 Vitra Pharmaceuticals Ltd., Saffron Walden Eisenverbindungen
US6846915B2 (en) 2001-08-13 2005-01-25 The Regents Of The University Of California Hydroxypyridonate and hydroxypyrimidinone chelating agents
GB0211500D0 (en) 2002-05-18 2002-06-26 Vitra Pharmaceuticals Ltd Method of forming iron hydroxypyrone compounds
US7595073B2 (en) * 2003-02-28 2009-09-29 Kraft Foods Global Brands Llc Use of siderophores and organic acids to retard lipid oxidation
GB0425555D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd Novel compounds
US8557601B2 (en) * 2006-07-10 2013-10-15 The Regents Of The University Of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
US7932326B2 (en) * 2008-04-16 2011-04-26 The University Of Kentucky Research Foundation Chelating compounds and immobilized tethered chelators
US9259670B2 (en) 2008-04-16 2016-02-16 The University Of Kentucky Research Foundation Flow-through filter to remove aluminum from medical solutions
US9139456B2 (en) 2008-04-16 2015-09-22 The Curators Of The University Of Missouri Chelating compounds and immobilized tethered chelators
US20100008864A1 (en) * 2008-07-10 2010-01-14 Andreas Meijer Aromatic multimers
US9273059B2 (en) 2009-08-24 2016-03-01 Lumiphore, Inc. Macrocyclic HOPO chelators
EP3263562A1 (de) * 2009-12-24 2018-01-03 Lumiphore, Inc. Radiopharmazeutische komplexe
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
CN106928132B (zh) * 2017-02-23 2020-07-24 苏州大学 一种羟基吡啶酮配体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3968118A (en) * 1968-08-31 1976-07-06 Hoechst Aktiengesellschaft Process for the manufacture of 1-hydroxy-2-pyridones
CA1049411A (en) * 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
GB2118176B (en) * 1982-03-24 1985-12-04 Nat Res Dev Pharmaceutical compositions
GR78491B (de) * 1982-03-24 1984-09-27 Nat Res Dev
EP0094149B1 (de) * 1982-03-24 1986-09-10 National Research Development Corporation Pharmazeutische Zusammensetzungen, die Eisen-Komplexe von N-substituierten 3-Hydroxypyrid-2-on- oder -4-on-Derivaten enthalten

Also Published As

Publication number Publication date
DK453684A (da) 1985-03-24
DK158349B (da) 1990-05-07
GB8423799D0 (en) 1984-10-24
GB2146989A (en) 1985-05-01
JPH02191254A (ja) 1990-07-27
EP0357150B1 (de) 1993-12-08
EP0138421A2 (de) 1985-04-24
DE3483713D1 (de) 1991-01-17
EP0138421B1 (de) 1990-12-05
JPH062740B2 (ja) 1994-01-12
GB2146989B (en) 1987-02-18
ZA847408B (en) 1986-05-28
EP0138421A3 (en) 1987-06-03
EP0357150A1 (de) 1990-03-07
DK453684D0 (da) 1984-09-21
JPS6094965A (ja) 1985-05-28
GB8325494D0 (en) 1983-10-26
GR80445B (en) 1985-01-23
DE3486255T2 (de) 1994-03-24
DK158349C (da) 1990-10-15
CY1516A (en) 1990-08-03
US4666927A (en) 1987-05-19
SG80989G (en) 1990-07-06
JPH062739B2 (ja) 1994-01-12

Similar Documents

Publication Publication Date Title
DE3486255D1 (de) Pharmazeutische Zusammensetzungen.
DE3483133D1 (de) Pharmazeutische zusammensetzungen.
DE3484098D1 (de) Pharmazeutische zusammensetzungen.
DE3485408D1 (de) Pharmazeutische zusammensetzung.
DE3863963D1 (de) Pharmazeutische zusammensetzungen.
DE3586545D1 (de) Erhoehte schmerzlosigkeit bewirkende pharmazeutische zusammensetzungen.
DE3868986D1 (de) Pharmazeutische zusammensetzungen.
ATE22007T1 (de) Pharmazeutische mischung.
FI901102A0 (fi) Farmaceutiska kompositioner.
FI922364A (fi) Farmaceutiska kompositioner.
DE3576117D1 (de) Mehrphasige pharmazeutische zusammensetzung.
IT8920486A0 (it) Composizioni farmaceutiche.
IT8820386A0 (it) Composizioni farmaceutiche orosolubili contenti acetilcisteina.
FI893643A (fi) Farmaceutiska kompositioner.
DE3382112D1 (de) Pharmazeutische zusammensetzung.
DE3682083D1 (de) Pharmazeutische zusammensetzungen.
FI872733A0 (fi) Farmaceutiska kompositioner.
FI872313A0 (fi) Farmaceutiska kompositioner.
FI883673A0 (fi) Farmaceutiska kompositioner.
DE3674040D1 (de) Pharmazeutische zusammensetzungen.
IT1213453B (it) Composizione farmaceutica.
FI852658A0 (fi) Farmaceutiska aemnen.
DE3483900D1 (de) Pharmazeutische zusammensetzungen.
ATE36455T1 (de) Pharmazeutische zusammensetzungen.
BE896711A (fr) Compositions pharmaceutiques anti-ulceres.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee